ReviewOncology letters2026
Research progress of pancreatic cancer based on ferroptosis-cuproptosis interaction (Review).
Review in Oncology letters, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Pancreatic cancer is a highly aggressive malignancy with a poor prognosis and pancreatic ductal adenocarcinoma (PDAC) constitutes the overwhelming majority of histological subtypes. KRAS mutation-driven metabolic reprogramming renders PDAC highly dependent on metal ion homoeostasis and antioxidant systems, thereby providing a novel rationale for therapeutic strategies targeting ferroptosis and cuproptosis. Ferroptosis is a form of regulated cell death caused by the excessive accumulation of iron-dependent lipid peroxidation, whereas cuproptosis is a newly characterised mode of cell death triggered by copper binding to mitochondrial lipoylated proteins, leading to proteotoxic stress. In PDAC, these two forms of cell death are not independent; rather, they interact through multiple metabolic and stress-response pathways. This review systematically summarizes the core molecular mechanisms of ferroptosis and cuproptosis, with particular emphasis on their crosstalk mediated by key nodes, including glutathione, mitochondria, the tricarboxylic acid cycle, iron-sulfur clusters and glutathione peroxidase 4. It further analyses how tumour microenvironmental factors, such as KRAS mutation, cancer-associated fibroblasts, hypoxia and epithelial-mesenchymal transition, regulate these two death programmes, and discusses their functional significance in drug resistance, cancer stem cells and the immune microenvironment. Finally, this review outlines PDAC therapeutic strategies based on the coordinated regulation of ferroptosis and cuproptosis, with the aim of providing a theoretical basis for the development of novel synergistic therapies targeting metal-dependent cell death in pancreatic cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.